Fudan University clinical trial pipeline

20 trials changed in the last 30 days: 0 stopped, 10 with notable changes, 10 with minor changes only.

1. Notable

   iPULSAR-CRC · Personalized Ultrafractionated Stereotactic…iPULSAR-CRC · Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

   Primary completion pushed from Mar 1, 2026 to Sep 30, 2029

   Also in this update: Study completion pushed from Mar 1, 2028 to Sep 30, 2030

   Fudan University·Phase 2· NCT06841159· Registry history of NCT06841159 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Notable

   TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

   Primary completion pushed from Jun 2026 to Jun 2029

   Also in this update: Study completion pushed from Jun 2028 to Jun 2032

   Fudan University·Phase 3· NCT05901428· Registry history of NCT05901428 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

3. Notable

   THUNDER · T-DXd With or Without Neratinib for HER2 Positive…THUNDER · T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

   Primary completion pushed from Nov 2027 to Aug 2029

   Also in this update: Recruitment opened; Study completion pushed from Nov 2029 to Nov 2031

   Fudan University·Phase 2· NCT07152782· Registry history of NCT07152782 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

4. Notable

   RECLAIM · Re-challenge Immunotherapy With Cromolyn, TQB2102…RECLAIM · Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

   Primary completion pushed from Jan 30, 2027 to Dec 31, 2027

   Also in this update: Study completion pushed from Apr 30, 2027 to Jun 30, 2028

   Fudan University·Phase 2· NCT07419880· Registry history of NCT07419880 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

5. Notable

   TORCH-PM02 · FAPI-Guided Radiotherapy With Cadonilimab and…TORCH-PM02 · FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)

   Recruitment opened

   Also in this update: Start date pushed from Sep 1, 2026 to Oct 1, 2026

   Fudan University·Phase 3· NCT07815834· Registry history of NCT07815834 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

6. Notable

   Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2…Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

   Enrollment reopened

   Fudan University·Phase 3· NCT06637150· Registry history of NCT06637150 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

7. Notable

   CDK4/6 Inhibitors Intensification for Chemotherapy Omission in…CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

   Recruitment opened

   Fudan University·Phase 3· NCT07432178· Registry history of NCT07432178 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

8. Notable

   Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or…Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

   Recruitment opened

   Also in this update: Enrollment increased: 154 → 196 participants

   Fudan University·Phase 3· NCT07132463· Registry history of NCT07132463 on ClinicalTrials.gov (opens the registry)

   Sep 21, 2026

9. Notable

   Calorite · Capecitabine in Low Risk Triple Negative Breast Cancer

   Recruitment opened

   Fudan University·Phase 2· NCT06787339· Registry history of NCT06787339 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

10. Notable

    THUMB · T-DXd With or Without Bevacizumab for HER2-low Breast…THUMB · T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

    Recruitment opened

    Fudan University·Phase 2· NCT07150208· Registry history of NCT07150208 on ClinicalTrials.gov (opens the registry)

    Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.